Filtered By:
Management: Insurance
Nutrition: Sodium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 52 results found since Jan 2013.
Dapagliflozin protects against doxorubicin-induced nephrotoxicity associated with nitric oxide pathway-A translational study
Free Radic Biol Med. 2023 Aug 5:S0891-5849(23)00585-3. doi: 10.1016/j.freeradbiomed.2023.08.013. Online ahead of print.ABSTRACTDoxorubicin (Dox) is a potent anticancer agent, but its associated organ toxicity, including nephrotoxicity, restricts clinical applications. Dapagliflozin (DAPA), a sodium-glucose cotransporter-2 inhibitor, has been shown to slow the progression of kidney disease in patients with and without diabetes. However, the effect of DAPA to counteract Dox-induced nephrotoxicity remains uncertain. Therefore, in this study, we aimed to elucidate the effects of DAPA in mitigating Dox-induced nephrotoxicity. W...
Source: Free Radical Biology and Medicine - August 7, 2023 Category: Biology Authors: Wei-Ting Chang Chia-Chun Wu I-Chuang Liao Yu-Wen Lin Yi-Chen Chen Chung-Han Ho Wei-Chieh Lee You-Cheng Lin Zhih-Cherng Chen Jhih-Yuan Shih Nan-Chun Wu Wei-Chih Kan Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
